Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry

Summary

The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.

Eligibility

Inclusion Criteria:

* Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy;
* All stages at the time of relapse;
* Histological grade 1-3a at the time of initial diagnosis;
* Age over 18 years;
* Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested
* Diagnostic material available for review;
* Written informed consent.

Exclusion Criteria:

• Age \< 18 years

Conditions3

Browse More Trials